Catalent (NYSE:CTLT) Sets New 52-Week High – Time to Buy?

Catalent, Inc. (NYSE:CTLT) shares hit a new 52-week high during trading on Monday . The stock traded as high as $62.28 and last traded at $62.25, with a volume of 899537 shares. The stock had previously closed at $61.83.

Wall Street Analyst Weigh In

CTLT has been the subject of several research reports. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com raised Catalent from a “sell” rating to a “hold” rating in a report on Monday, December 2nd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The firm has a 50 day moving average price of $60.07 and a two-hundred day moving average price of $58.74.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the business earned ($0.10) earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Equities research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last three months. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Brooklyn Investment Group bought a new position in Catalent in the 3rd quarter worth $31,000. Sentry Investment Management LLC bought a new position in Catalent in the 3rd quarter worth $53,000. Longfellow Investment Management Co. LLC raised its holdings in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its holdings in Catalent by 57.5% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the period. Finally, Intact Investment Management Inc. bought a new position in Catalent in the 3rd quarter worth $73,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.